Recently, Reddit user Musikcookie took to the popular Ask Reddit page to ask doctors, "What was the wildest self-diagnoses a ...

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.

Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.

Leukemia warriors unlock miraculous healing powers as breakthrough treatments revolutionize cancer survival forever.

Colorado physicians helped research a new treatment protocol for the most common form of childhood cancer that has “instantly ...

Shares of Curis jumped after the company released what it assessed as positive data from a study of its in-development treatment for leukemia. The stock was up 33%, to $4.07, in midday trading ...

The global leukemia therapeutics treatment market has seen considerable growth, progressing from USD 14,504.8 million in 2022 to USD 15,246.7 million in 2023. With a projected compound annual growth ...

And an active area of research now is trying to identify which of those patients may be at higher risk of developing ...

Revumenib displayed promising anti-tumor activity among patients with relapsed or refractory KMT2Ar acute leukemia.

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on ...

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...